The FDA Roundtable Part II: REMS, Outcomes Studies and Drug Withdrawals
This article was originally published in RPM Report
In Part II of The RPM Report’s roundtable discussion with three top FDA officials, the importance and implementation of FDA’s new REMS authorities, drug withdrawal precedents and the agency’s view of outcomes studies are the focus of the discussion.
You may also be interested in...
The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
FDA’s top drug regulator sat down for us for an interview about the agency’s efforts to build a higher quality regulatory system in the US—one that focuses on the “content” of regulatory standards rather than just the process. The discussion touched on the need for new and improved standards in classes like weight loss and rheumatology (albeit for very different reasons); the characteristics that make for good drug reviewers (and their managers); and on the drug center’s responsibility for preserving private sector drug development.
There are new considerations for developing diabetes drugs when it comes to FDA's expectations. Here are some of the questions to consider.
GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early